Skip to main content
SpringerLink
Log in

A conservative approach to treatment is appropriate for Raynaud’s phenomenon

  • New Drugs and Therapeutic
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Blombery P. Raynaud’s phenomenon. New Ethicals 1993 Nov; 30: 81–7

    Google Scholar 

  2. Isenberg DA, Black C. Raynaud’s phenomenon, scleroderma, and overlap syndromes. BMJ 1995 Mar 25; 310: 795–8

    Article  PubMed  CAS  Google Scholar 

  3. Coffman JD. Raynaud’s phenomenon: an update. Hypertension 1991 May; 17(5): 593–602

    Article  PubMed  CAS  Google Scholar 

  4. Weber A, Bounameaux H. Effects of low-dose nifedipine on a cold provocation test in patients with Raynaud’s disease. J Cardiovas Pharmacol 1990; 15(5): 853–5

    Article  CAS  Google Scholar 

  5. British National Formulary No. 29. London: The Pharmaceutical Press, 1995; 94–5, 81

  6. Grant SM, Goa KL. Iloprost: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peripheral vascular disease, myocardial ischaemia and extracorporeal circulation procedures. Drugs 1992 Jun; 43(6): 889–924

    Article  PubMed  CAS  Google Scholar 

  7. Wigley FM, Wise RA, Seibold JR, et al. Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. Ann Intern Med 1994 Feb 1; 120(3): 199–206

    PubMed  CAS  Google Scholar 

  8. Belch JJF, Capell HA, Cooke ED, et al. Oral iloprost as a treatment for Raynaud’s syndrome: a double-blind multicentre placebo controlled study. Ann Rheum Dis 1995; 34: 636–41

    Google Scholar 

  9. Lau CS, Belch JJF, Madhok R, et al. A randomised, double-blind study of cicaprost, an oral prostacyclin analogue, in the treatment of Raynaud’s phenomenon secondary to systemic sclerosis. Clin Exper Rheum 1993; 11: 35–40

    CAS  Google Scholar 

  10. Challenor VF. Angiotensin converting enzyme inhibitors in Raynaud’s phenomenon. Drugs 1994; 48(6): 864-7

    Article  PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

A conservative approach to treatment is appropriate for Raynaud’s phenomenon. Drugs Ther. Perspect 6, 6–8 (1995). https://doi.org/10.2165/00042310-199506090-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-199506090-00003

Search

Navigation